Since 2019, the Advanced Heart and Lung Disease Center at Baylor Scott & White All Saints Medical Center – Fort Worth has offered a specialized approach to managing patients with heart failure. While the center provides options for heart failure in its most advanced stage, it also focuses on preventing the progression of the condition.
Baylor Scott & White Heart and Vascular Hospital – Fort Worth is actively recruiting for a study of cardiac contractility modulation (CCM) in a new group of heart failure patients. The AIM HIGHer study will evaluate the efficacy and safety of implantable CCM therapy in those with symptomatic heart failure and an ejection fraction (EF) between 40 and 60%.
The Valve Disorders Center at Baylor Scott & White Heart and Vascular Hospital – Fort Worth offers streamlined access to experts in valve disease for physicians and their patients. By bringing together a dedicated team from multiple specialties, including cardiothoracic surgeons on the medical staff of Baylor Scott & White All Saints Medical Center – Fort Worth, patients with valve disorders get a comprehensive evaluation and access to innovative treatments in one place.
The vascular program at Baylor Scott & White All Saints Medical Center – Fort Worth recently performed Tarrant County’s first fenestrated abdominal aortic aneurysm surgery, or FEVAR.
In April, the American College of Cardiology (ACC), American Heart Association (AHA) and the Heart Failure Society of America (HFSA) issued new joint guidelines for managing patients with heart failure. The most striking update to the guidelines is the addition of sodium-glucose co-transporter 2 inhibitors or SGLT2 inhibitors to guideline-directed medical therapy.
